Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Blueberries Medical Corp. is a Canadian-based life sciences company focused on the medical cannabis industry, with primary operations in Latin America, particularly Colombia. The company’s core business involves the cultivation, processing, and commercialization of pharmaceutical-grade cannabis for medical and scientific purposes, operating within regulated frameworks. Blueberries Medical positions itself as a vertically integrated producer aimed at supplying both domestic and international medical cannabis markets.
The company’s primary revenue drivers are expected to come from the production and sale of cannabis-derived active pharmaceutical ingredients (APIs), dried flower, and extracts for medical use, although revenue generation has historically been limited. Blueberries Medical targets pharmaceutical companies, medical distributors, and regulated healthcare channels rather than the recreational cannabis market. Its strategic positioning emphasizes low-cost cultivation, favorable growing conditions, and regulatory access in Colombia. The company was incorporated in Canada in 2019 and went public as part of a wave of cannabis-focused issuers seeking exposure to emerging international medical markets.
Business Operations
Blueberries Medical operates through a vertically integrated model encompassing cultivation, extraction, and commercialization of medical cannabis. Its operations are primarily conducted through its Colombian subsidiaries, which hold licenses for cannabis cultivation, processing, and derivative production under Colombian federal regulations. The company’s assets include greenhouse cultivation facilities, extraction capabilities, and regulatory permits tied to medical cannabis production.
The company has minimal commercial operations in Canada, with corporate management and public company functions handled domestically, while nearly all operational activity occurs in Colombia. Blueberries Medical has disclosed reliance on third-party service providers and strategic partners for certain processing, logistics, and market access functions. Revenue generation has been inconsistent, and public disclosures indicate the company remains in a development and early commercialization stage, with ongoing efforts to secure supply agreements and export channels.
Strategic Position & Investments
Blueberries Medical’s strategic direction centers on building scale in international medical cannabis supply chains, particularly for export-oriented pharmaceutical markets. The company has invested in cultivation infrastructure and licensing in Colombia to leverage the country’s cost advantages and export-friendly regulatory framework. Management has publicly emphasized achieving EU-GMP-aligned standards, although full certification status has varied over time based on public disclosures.
The company has pursued selective acquisitions and restructuring initiatives aimed at consolidating its Colombian operations, including ownership interests in licensed local entities. Blueberries Medical has also highlighted its intention to participate in emerging segments such as cannabis-based pharmaceuticals and research applications, though material commercial progress in these areas remains limited based on available public filings. Where disclosures conflict regarding production scale or commercialization timelines, data is inconclusive based on available public sources.
Geographic Footprint
Blueberries Medical is headquartered in Canada, with its principal operational footprint in Colombia, which serves as the company’s cultivation and processing hub. The Colombian operations are strategically located to support exports to Latin America, Europe, and other international medical cannabis markets where regulations permit.
The company does not report significant operating assets in North America outside Canada, nor in Asia-Pacific or Africa, but has indicated long-term interest in expanding international distribution through partnerships. Its geographic influence is therefore concentrated in Colombia, with Canada functioning primarily as a corporate and capital markets base rather than a production center.
Leadership & Governance
Blueberries Medical is led by an executive team with experience in cannabis operations, international business, and public company governance. The company has undergone multiple leadership changes since inception, reflecting its evolving strategy and restructuring efforts.
Key executives include:
- José María López – Chief Executive Officer
- Marco Schurmann – President and Director
- Alexandre Veyrat – Chief Financial Officer
- Daniel Laflamme – Director
Management has articulated a strategy focused on disciplined capital allocation, regulatory compliance, and building a sustainable export-oriented medical cannabis platform. Corporate governance follows Canadian public company standards, with oversight provided by an independent board, as disclosed in SEC filings and Canadian continuous disclosure documents.